Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof
The present disclosure relates to novel imidazo[1,2-a]pyridine derivatives, and more particularly to imidazo[1,2-a]pyridine derivatives of Formula 1 wherein Y 1 , Y 2 and Y 3 are each independently H, halogen, a C 1 -C 6 straight chain alkyl unsubstituted or substituted with R 1 , or hydroxy; R 1 is hydroxy; Y 4 is H, C 1 -C 6 straight chain alkyl, or C 1 -C 6 alkoxy; and X is H or halogen, and having an excellent activity of inhibiting gastric acid secretion, methods for preparing the same, and the use thereof. The imidazo[1,2-a]pyridine derivatives according to the present disclosure have gastric acid secretion inhibitory activity, and thus may be effectively used for the prevention or treatment of gastrointestinal inflammatory diseases or gastric acid-related diseases.
1. An imidazo[1,2-a]pyridine derivative represented by the following formula 1 or a pharmaceutically acceptable salt thereof:
wherein
Y 1 , Y 2 and Y 3 are each independently H, halogen, a C 1 -C 6 straight chain alkyl unsubstituted or substituted with R 1 , or hydroxy;
R 1 is hydroxy;
Y 4 is H, C 1 -C 6 straight chain alkyl, or C 1 -C 6 alkoxy; and
X is H or halogen.
2. The imidazo[1,2-a]pyridine derivative or the pharmaceutically acceptable salt thereof according to claim 1 , wherein
Y 1 is H or a C 1 -C 3 straight chain alkyl substituted with R 1 ;
Y 2 and Y 3 are each independently H, F, a C 1 -C 3 straight chain alkyl unsubstituted or substituted with R 1 or hydroxy;
R 1 is hydroxy;
Y 4 is H, C 1 -C 3 straight chain alkyl, or C 1 -C 3 alkoxy; and
X is H, F, or Cl.
3. The imidazo[1,2-a]pyridine derivative or the pharmaceutically acceptable salt thereof according to claim 2 , wherein
y is H;
Y 2 and Y 3 are each independently H, F, a C 1 -C 2 straight chain alkyl unsubstituted or substituted with R 1 , or hydroxy;
R 1 is hydroxy;
Y 4 is H or C 1 -C 2 straight chain alkyl; and
X is H or F.
4. The imidazo[1,2-a]pyridine derivative or the pharmaceutically acceptable salt thereof according to claim 3 , wherein
Y 1 is H;
Y 2 and Y 3 are each independently H, F, methyl, hydroxymethyl, or hydroxy;
Y 4 is H or methyl; and
X is H or F.
5. The imidazo[1,2-a]pyridine derivative or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the derivative represented by formula 1 is selected from the group consisting of the following compounds:
1) {8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxyazetidin-1-yl)methanone;
6) azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone;
7) {8-[(2,6-dimethyl)benzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-fluoroazetidin-1-yl)methanone;
8) {8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-methylazetidin-1-yl)methanone;
9) {8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxy-3-methylazetidin-1-yl)methanone;
11) {8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}[3-(hydroxymethyl)azetidin-1-yl]methanone;
17) {8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo [1,2-a]pyridin-6-yl}[2-(hydroxymethyl)azetidin-1-yl]methanone;
20) {8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}[3-(2-hydroxyethyl)azetidin-1-yl]methanone;
23) {2,3-dimethyl-8-[(2-methylbenzyl)amino]imidazo[1,2-a]pyridin-6-yl}(3-hydroxyazetidin-1-yl)methanone;
24) {8-[(5-fluoro-2-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxyazetidin-1-yl)methanone;
25) (3-hydroxyazetidin-1-yl){8-[(2-methoxy-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)methanone;
26) [3-(hydroxymethyl)azetidin-1-yl]{8-[(2-methoxy-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)}methanone;
27) {8-[(4-fluoro-2-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxyazetidin-1-yl)methanone;
28) azetidin-1-yl {8-[(4-fluoro-2-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)}methanone;
29) {8-[(4-fluoro-2-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-fluoroazetidin-1-yl)methanone;
30) {8-[(4-fluoro-2-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-methylazetidin-1-yl)methanone;
31) {8-[(4-fluoro-2-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxy-3-methylazetidine-1-yl)methanone;
33) {8-[(4-fluoro-2-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-(hydroxymethyl)azetidin-1-yl)methanone;
34) {8-[(4-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxyazetidin-1-yl)methanone;
35) azetidin-1-yl{8-[(4-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone;
36) {8-[(4-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-fluoroazetidin-1-yl)methanone;
37) {8-[(4-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-methylazetidin-1-yl)methanone;
38) {8-[(4-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxy-3-methylazetidin-1-yl)methanone;
39) {8-[(4-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}[3-(hydroxymethyl)azetidin-1-yl]methanone;
41) {8-[(3-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxyazetidin-1-yl)methanone;
42) azetidin-1-yl{8-[(3-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone;
43) {8-[(3-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-fluoroazetidin-1-yl)methanone;
44) {8-[(3-fluoro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}[3-(hydroxymethyl)azetidin-1-yl]methanone;
45) azetidin-1-yl{8-[(3-chloro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone;
46) {8-[(3-chloro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-hydroxyazetidin-1-yl]methanone;
47) {8-[(3-chloro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}(3-fluoroazetidin-1-yl)methanone; and
48) {8-[(3-chloro-2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}[3-(hydroxymethyl)azetidin-1-yl]methanone.
6. A pharmaceutical composition for treating gastrointestinal inflammatory disease or a gastric acid-related disease, the composition containing, as an active ingredient, an imidazo[1,2-a]pyridine derivative or a pharmaceutically acceptable salt thereof according to claim 1 .
7. The pharmaceutical composition of claim 6 , wherein the gastrointestinal inflammatory disease or the gastric acid-related disease is selected from the group consisting of peptic ulcer, gastric and duodenal ulcer, nonsteroidal anti-inflammatory drug (NSAID)-induced ulcer, Helicobacter pylori infection, functional indigestion, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease (GERD), and nonerosive reflux disease (NERD).
8. A method for treating a disease caused by excessive secretion of gastric acid, the method comprising administering a therapeutically effective amount of an imidazo[1,2-a]pyridine derivative or a pharmaceutically acceptable salt thereof according to claim 1 .